Known targets — ChEMBL curated mechanism
CDK1CDK10CDK11BCDK12CDK13CDK14CDK15CDK16CDK17CDK18CDK19CDK2CDK20CDK3CDK4CDK5CDK6CDK7CDK8CDK9
The experimentally established mechanism targets of At-7519. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 11/20 | 1.00 |
| ▸ | CDK14 known ✓ | O94921 | 9/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 5/20 | 1.00 |
| ▸ | CDK5 known ✓ | Q00535 | 3/20 | 1.00 |
| ▸ | CDK4 known ✓ | P11802 | 2/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 2/20 | 1.00 |
| ▸ | CDK11B known ✓ | P21127 | 1/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 1/20 | 1.00 |
| ▸ | CDK3 known ✓ | Q00526 | 1/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 1.00 |
| ▸ | CDK16 known ✓ | Q00536 | 1/20 | 1.00 |
| ▸ | CDK17 known ✓ | Q00537 | 1/20 | 1.00 |
| ▸ | CDK18 known ✓ | Q07002 | 1/20 | 1.00 |
| ▸ | CDK13 known ✓ | Q14004 | 1/20 | 1.00 |
| ▸ | CDK15 known ✓ | Q96Q40 | 1/20 | 1.00 |
| ▸ | CDK19 known ✓ | Q9BWU1 | 1/20 | 1.00 |
| ▸ | CDK12 known ✓ | Q9NYV4 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 9/20 | 1.00 |
| ▸ | CCNY | Q8ND76 | 9/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| At-7519 SCHEMBL29686205 | 0.99 | CDK2 (0.98) | CDK2CCNA2CDK14CCNYCDK1 | |
| At-7519 SCHEMBL29369459 | 0.95 | CDK14 (0.90) | CDK2CCNA2CDK14CCNYCDK1 | |
| At-7519 SCHEMBL30439334 | 0.93 | CDK2 (1.00) | CDK2CCNA2CDK14CCNYCDK1 | |
| SCHEMBL17252164 | 0.83 | CDK14 (0.70) | CDK2CCNA2CDK14CCNYCDK1 | |
| At-7519 SCHEMBL955568 | 0.78 | CDK5 (0.67) | CDK2CCNA2CDK14CCNYCDK1 | |
| At-7519 SCHEMBL31046986 | 0.77 | CDK5 (0.66) | CDK2CCNA2CDK14CCNYCDK1 | |
| At-7519 SCHEMBL953647 | 0.77 | CDK5 (0.66) | CDK2CCNA2CDK14CCNYCDK1 | |
| At-7519 SCHEMBL1069453 | 0.74 | CDK5 (0.62) | CDK2CCNA2CDK14CCNYCDK1 | |
| SCHEMBL30915451 | 0.74 | CDK5 (0.60) | CDK2CCNA2CDK14CCNYCDK1 | |
| SCHEMBL22594270 | 0.74 | CDK14 (0.59) | CDK2CCNA2CDK14CCNYCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY | 2022-10-13 | — | — | US | claimed |
| WO-2020223609-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY (US) | 2020-11-05 | — | — | WO | claimed |
| US-10351916-B2 | Method for identification of anti-HIV human miRNA mimics and miRNA inhibitors and anti-HIV pharmaceutical compounds | CSIR (ZA) | 2019-07-16 | — | — | US | claimed |
| WO-2025217597-A1 | A CDK9 INHIBITOR FOR USE IN THE TREATMENT OF CANCER IN A SUBJECT HAVING AN ASXL1 MUTATION | Sellas Life Sciences Group, Inc. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20240350497-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAN-KRAS MUTATED CANCERS | TIZIANA LIFE SCIENCES PLC (GB) | 2024-10-24 | — | — | US | disclosed |
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-12 | — | — | US | disclosed |
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240252688-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. | 2024-08-01 | — | — | US | disclosed |
| EP-4384144-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAN-KRAS MUTATED CANCERS | Tiziana Life Sciences PLC (GB) | 2024-06-19 | — | — | EP | disclosed |
| CN-117642169-A | Use of a selective estrogen receptor covalent antagonist in combination with a CDK4/6 inhibitor for the treatment of breast cancer | 江苏恒瑞医药股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4126244-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023284790-A1 | USE OF SELECTIVE ESTROGEN RECEPTOR COVALENT ANTAGONIST IN COMBINATION WITH CDK4/6 INHIBITOR IN THE PREPARATION OF MEDICINE FOR TREATING BREAST CANCER | 江苏恒瑞医药股份有限公司 | 2023-01-19 | — | — | WO | disclosed |
| WO-2022266491-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022261220-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY | 2022-10-13 | — | — | US | disclosed |
| CN-109803684-B | Combination therapy for the treatment of hepatocellular carcinoma | 卫材 R&D 管理有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-114245753-A | Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy | 江苏康宁杰瑞生物制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| WO-2020223609-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350497-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAN-KRAS MUTATED CANCERS | KRAS, NRAS, BRCA1 | CDK2 27/4885CDK14 46/4885CDK1 28/4885 |
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | BCL3, MCL1, BCL2 | CDK2 741/4885CDK14 2843/4885CDK1 1853/4885 |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | MCL1, BAX, CASP3 | CDK2 894/4885CDK14 1511/4885CDK1 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.